BMO Capital Cuts PT on BioNTech SE (BNTX) to $128 From $143 – Here’s Why

Core Viewpoint - BioNTech SE (NASDAQ:BNTX) is facing uncertainty due to leadership changes and underwhelming COVID guidance, despite being considered a high-growth healthcare stock [1][2] Group 1: Price Target Adjustments - BMO Capital reduced the price target for BioNTech to $128 from $143 while maintaining an Outperform rating [1] - Morgan Stanley also cut its price target to $125 from $134 but kept an Overweight rating, citing the leadership transition overshadowing fiscal Q4 results [2] Group 2: Leadership and Guidance Concerns - The company's leadership transition coincided with its Q4 report, creating uncertainty ahead of a significant year for data [2] - The 2026 COVID guidance was described as underwhelming, contributing to investor concerns [1] Group 3: Company Overview - BioNTech SE is a German biotechnology firm specializing in messenger RNA (mRNA) therapeutics and vaccines for serious diseases, including cancer and infectious diseases [3]